We just published Gibson Dunn’s 2026 Royalty Finance Market Update — a comprehensive analysis of 133 life sciences royalty transactions from 2020 through 2025, totaling $32.7 billion in aggregate value. A few findings stood out to us as genuinely worth flagging for practitioners in the space.
The market is rate-resilient, and that’s now empirically established.
Annual deal volume held steady at 25–27 transactions per year even as the federal funds rate climbed above 5% — a level most practitioners would have assumed would suppress deal activity. It didn’t. The 2022 contraction (deal value fell to $3.9B) was driven by rate volatility — the speed and uncertainty of the Fed’s 425 bps tightening cycle — not by rate levels. Once rates stabilized, deal flow recovered sharply and reached record levels. For boards and advisors weighing the timing of a royalty transaction, this matters: the window is open in any rate-stable environment.
True-sale synthetics are now the market standard.
In 2020–2021, roughly half of synthetic royalty transactions were structured as true sales. By 2024–2025, that figure reached 71% of deals and 91% of synthetic deal value. The shift — catalyzed in 2020 and now broadly adopted across the buyer landscape — reflects a decisive market preference for covenant-light, non-debt capital structures. Sellers should understand that the debt-structured alternative still exists and carries its own advantages (potentially lower effective cost of capital, no upfront tax recognition), but true-sale is now the default to benchmark against.
Seller economics have improved meaningfully.
Cap multiples on capped synthetic deals range from 1.55x to 4.0x, with a median of 2.0x — but increasingly, the terms are asset-specific rather than market-driven. Tiered rate structures (where the royalty rate declines as product sales scale) are now common and represent a genuine economic improvement for sellers of high-conviction assets. Buyback options are emerging as a standard deal point. The days of buyers setting terms unilaterally are over.
The full report covers the competitive buyer landscape, the bifurcation of clinical funding into two distinct sub-markets, hybrid deal structures, and our outlook for 2026 — including why drug pricing reform (IRA + MFN) represents the most significant structural risk to royalty valuations in the out-years.
The report is available at gibsondunn.com, along with our Royalty Finance Tracker — a publicly accessible database of all 133 transactions in the dataset.
This publication is for general informational purposes only and does not constitute legal advice. Gibson, Dunn & Crutcher LLP. © 2026.